Gamida Cell Ltd (GMDAQ)

[midastouch017]

Gamida Cell price target raised to $25 from $13 at
Piper Sandler Piper Sandler analyst Edward Tenthoff
raised the firm's price target on Gamida Cell to $25
from $13 and keeps an Overweight rating on the shares.
The analyst is citing the company's Phase 3 omidubicel
data presented at the TCT Annual Meeting that showed
"significantly lowered rate of serious infection" and
reduced hospital stay.
Tenthoff adds that along with
less stringent HLA matching requirements, omidubicel
can dramatically expand access and improve outcomes
for HSCT patients, further stating that he is
increasing his modeled value on omidubicel to
$793M from $550M

https://thefly.com/landingPageNews.php?id=3244394&headline=GMDA-Gamida-Cell-price-target-raised-to--from--at-Piper-Sandler